Please Wait.....
Report
France Diabetes Devices - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)
Market Report I 2025-07-01 I 80 Pages I Mordor Intelligence
France Diabetes Devices Market Analysis
The France diabetes devices market reached USD 1.39 billion in 2025 and is projected to attain USD 1.91 billion by 2030, equating to a 6.58% CAGR and pointing to steady mid-single-digit expansion over the next five years. This momentum reflects the world-first decision by France to reimburse continuous glucose monitoring (CGM) for every insulin user, including the 100,000 people with Type 2 diabetes who received coverage for Dexcom ONE in mid-2024. Reimbursement removes cost barriers, so hospitals, diabetes specialty centers, and general practitioners prescribe sensors earlier in the care pathway. Public-private grants through France 2030 and the Important Project of Common European Interest (IPCEI) for Health reinforce domestic semiconductor capacity, cutting reliance on foreign sensors and stabilizing supply chains. Meanwhile, the "Mon Espace Sante" platform integrates real-time glucose data with electronic health records, streamlining teleconsultation, which rose six-fold among general practitioners between 2022 and 2024. Together, reimbursement, state funding, and digital connectivity give the France diabetes devices market a structural growth foundation that remains resilient to macro-economic swings.
France Diabetes Devices Market Trends and Insights
Rising diabetes prevalence & an aging population
Roughly 3.5 million French citizens live with diabetes, up from 2024 levels, and prevalence in men already ranges 3-5%. Incidence of Type 1 diabetes in children nearly tripled between the 1994-2003 and 2013-2022 periods. Higher case counts, longer lifespans, and more complex comorbidities boost durable demand for CGM, patch pumps, and data-driven care. As seniors adopt smartphones, CGM apps scale into older age brackets, widening revenue pools in the France diabetes devices market.
Patient-centric move to home care & telemonitoring
The state-run "Mon Espace Sante" portal lets patients push CGM data directly to physicians, enabling virtual dose adjustments and lowering travel burdens. Teleconsultations jumped six-fold since COVID-19, and remote prescribers can now bill for digital follow-ups under July 2023 reimbursement rules. Pharmacists, nurses, and dietitians receive real-time dashboards, creating a multidisciplinary continuum that raises adherence and reduces acute admissions. These changes stimulate sustained CGM reorder cycles, particularly in remote regions with fewer endocrinologists.
Stringent CEPS price caps compress margins
The Economic Committee for Health Products mandates pricing tied to clinical-benefit scores, limiting premium surcharges even for breakthrough devices. Hospitals must run competitive tenders that weigh price above features, squeezing suppliers. Manufacturers respond by shifting to subscription models where analytics and coaching carry extra value, but margin headroom remains thin across the France diabetes devices market.
Other drivers and restraints analyzed in the detailed report include:
Government & EU funding strengthens local supply / Hybrid closed-loop & patch-pump innovation / Regulatory complexity prolongs certification /
For complete list of drivers and restraints, kindly check the Table Of Contents.
Segment Analysis
Monitoring devices generated 57.13% of revenue in 2025, underlining data's central role in the France diabetes devices market. CGM overtakes self-monitoring blood glucose (SMBG) as reimbursement widens; Dexcom ONE coverage alone added 0.1 million Type 2 users. The France diabetes devices market size for monitoring devices equaled USD 0.79 billion in 2025 and is forecast to exceed USD 1.10 billion by 2030, implying a sensor unit CAGR ahead of total market due to falling average selling prices. Factory-calibrated Libre 3 sensors from Abbott provide 14-day wear without finger-stick confirmation, supporting rapid replacement cycles. Domestic fab capacity under France 2030 could lower BOM costs by 2027 and help new entrants attack price-sensitive segments.
Management devices-pens, pumps, and closed-loop systems-grow 3.10% annually from a smaller base. Updated 2024 guidelines extend AID to new cohorts, improving user confidence. The France diabetes devices market size for management devices reached USD 0.60 billion in 2025 and may touch USD 0.81 billion by 2030. Trials like RADIANT assess direct leaps from injections to full automation, potentially opening a pipeline of 450,000 pump-naive adults. As sensors and pumps bundle, ecosystem lock-in intensifies, prompting third-party app developers to seek interoperable Bluetooth standards to safeguard user choice in the France diabetes devices market.
The Report Covers France's Diabetes Device Market Trends and It is Segmented by Device Type (Monitoring Devices and Management Devices), End User (Hospitals & Clinics, Home-Care Settings, and More), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Sales). The Market Provides the Value (in USD) for the Above-Mentioned Segments.
List of Companies Covered in this Report:
Abbott Laboratories / Roche / Dexcom / Medtronic / Insulet / Tandem Diabetes Care / Ypsomed / Novo Nordisk / Eli Lilly and Company / Sanofi / Becton Dickinson & Co. / Lifescan LLC / Ascensia / Senseonics / Owen Mumford / Diabeloop SA / Med-tronic (France) SAS /
Additional Benefits:
The market estimate (ME) sheet in Excel format /
3 months of analyst support /
1 Introduction
1.1 Study Assumptions & Market Definition
1.2 Scope of the Study
2 Research Methodology
3 Executive Summary
4 Market Landscape
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Diabetes Prevalence And An Aging French Population Expanding The Addressable Device User Base
4.2.2 Patient-Centric Shift Toward Home-Based Self-Management And Telemonitoring Supported By "Mon Espace Sante" Digital-Health Infrastructure
4.2.3 Nationwide Expansion Of Reimbursement (Lppr Listings)
4.2.4 Ongoing Technology Improvements
4.2.5 Government And Eu Funding (France 2030, Ipcei Health) Stimulating Domestic R&D And Sensor Manufacturing Capacity
4.2.6 Emergence Of Hybrid Closed-Loop And Patch-Pump Solutions Offering Superior Glycemic Control And Quality-Of-Life Benefits
4.3 Market Restraints
4.3.1 Stringent Ceps Price Caps And Tendering Processes Compressing Manufacturer Margins And Discouraging New Entrants
4.3.2 Complex Eu-Mdr Compliance And Ansm Cybersecurity Mandates Prolonging Certification Timelines And Raising Regulatory Costs
4.3.3 Shortage Of Diabetes-Specialist Nurses
4.3.4 GLP-1 Therapy Reducing Smbg Frequency
4.4 Value / Supply-Chain Analysis
4.5 Regulatory & Reimbursement Outlook
4.6 Technological Outlook
4.7 Porter's Five Forces Analysis
4.7.1 Bargaining Power of Buyers
4.7.2 Bargaining Power of Suppliers
4.7.3 Threat of New Entrants
4.7.4 Threat of Substitutes
4.7.5 Intensity of Competitive Rivalry
5 Market Size & Growth Forecasts (Value)
5.1 By Device Type
5.1.1 Monitoring Devices
5.1.1.1 Self-Monitoring Blood Glucose Devices
5.1.1.1.1 Glucometers (smart/basic)
5.1.1.1.2 Test Strips
5.1.1.1.3 Lancets
5.1.1.2 Continuous Glucose Monitoring
5.1.1.2.1 Sensors
5.1.1.2.2 Transmitters & Receivers
5.1.1.2.3 Durables (Transmitters, Re-useable Parts)
5.1.2 Management Devices
5.1.2.1 Insulin Delivery Devices
5.1.2.1.1 Insulin Pumps
5.1.2.1.2 Insulin Pump Resorvoir
5.1.2.1.3 Infusion Sets
5.1.2.1.4 Insulin Pens
5.1.2.1.5 Insulin Catridges
5.2 By End User
5.2.1 Hospitals & Clinics
5.2.2 Home-care Settings
5.2.3 Diabetes Specialty Centres
5.2.4 Ambulatory Surgical Centres
5.2.5 Pharmacies & Retail Outlets
5.3 By Distribution Channel
5.3.1 Hospital Pharmacies
5.3.2 Retail Pharmacies
5.3.3 Online Sales
6 Market Indicators
6.1 Type-1 Diabetes Population
6.2 Type-2 Diabetes Population
7 Competitive Landscape
7.1 Market Concentration
7.2 Strategic Moves (M&A, Partnerships, Funding)
7.3 Market Share Analysis
7.4 Company Profiles {(includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)}
7.4.1 Abbott Laboratories
7.4.2 Roche Diabetes Care
7.4.3 Dexcom Inc.
7.4.4 Medtronic plc
7.4.5 Insulet Corporation
7.4.6 Tandem Diabetes Care
7.4.7 Ypsomed AG
7.4.8 Novo Nordisk A/S
7.4.9 Eli Lilly and Company
7.4.10 Sanofi S.A.
7.4.11 Becton Dickinson & Co.
7.4.12 Lifescan LLC
7.4.13 Ascensia Diabetes Care
7.4.14 Senseonics Holdings Inc.
7.4.15 Owen Mumford Ltd.
7.4.16 Diabeloop SA
7.4.17 Med-tronic (France) SAS
8 Market Opportunities & Future Outlook
8.1 White-space & Unmet-need Assessment
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security